2024
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology
Rahman R, Shi D, Reitman Z, Hamerlik P, de Groot J, Haas-Kogan D, D’Andrea A, Sulman E, Tanner K, Agar N, Sarkaria J, Tinkle C, Bindra R, Mehta M, Wen P. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro-Oncology 2024, 26: 1367-1387. PMID: 38770568, PMCID: PMC11300028, DOI: 10.1093/neuonc/noae072.Peer-Reviewed Original ResearchConsensus reviewDNA damage responseIDH wild-type glioblastomaIDH-mutant gliomasClinical trial design considerationsMechanisms of resistanceTrial design considerationsCombination therapyDevelopment of DDR inhibitorsDNA damage response pathwayPreclinical modelsDamage responseDDR inhibitorsNeuro-oncologyBrain tumorsBiomarker developmentTherapyResponse to DNA damageDNA damageTranslational effortsTumor
2023
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
Kiluk B, Kleykamp B, Comer S, Griffiths R, Huhn A, Johnson M, Kampman K, Pravetoni M, Preston K, Vandrey R, Bergeria C, Bogenschutz M, Brown R, Dunn K, Dworkin R, Finan P, Hendricks P, Houtsmuller E, Kosten T, Lee D, Levin F, McRae-Clark A, Raison C, Rasmussen K, Turk D, Weiss R, Strain E. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder. JAMA Psychiatry 2023, 80: 84-92. PMID: 36449315, PMCID: PMC10297827, DOI: 10.1001/jamapsychiatry.2022.4020.Peer-Reviewed Original ResearchConceptsOpioid use disorderOUD treatmentUse disordersClinical trial design challengesAddiction Clinical Trial TranslationsΜ-opioid receptor systemNetworks (ACTTION) public-private partnershipTrial design challengesOngoing opioid epidemicTrial design considerationsClinical trial design considerationsRole of treatmentQuality of lifeAntagonist medicationsEmerging TreatmentsAdverse eventsOpioid usePrimary outcomeStages of treatmentPatient preferencesMOR agonistsOpioid epidemicConsensus recommendationsCurrent evidenceTreatment retention
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply